GLP1R and rheumatoid arthritis: In sensitivity analyses, risk of all-cause mortality after overlap weighting was similarly lower with GLP-1-RA exposure when patients with prior MI or ischemic stroke were excluded (HR 0.42 [0.24–0.75], RD -8.5 [-14.9 to -2.0]), when patients who discontinued therapy within 3 months of initiation were excluded (HR 0.46 [0.28–0.75], RD -8.6 [-14.8 to -2.0]), and when an intention-to-treat approach (where follow up was 4.92 and 4.82 years in GLP-1-RA- and DPP-4i-exposed groups, respectively) was employed (HR 0.72 [0.60–0.86], RD -6.8 [-11.7 to -1.9]).